Cagrilintide vs DSIP
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | DSIP |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | May cause grogginess upon waking, vivid dreams, or temporary headaches. |
| Best For |
Key Differences
Unique to Cagrilintide:
Unique to DSIP:
Detailed Analysis
Cagrilintide and DSIP are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Cagrilintide for Fat Loss. Choose DSIP for Recovery & Healing, Sleep Quality.